Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412263 | 0.76 | BACE1 (0.32) | — | |
| SCHEMBL14395517 | 0.76 | CA2 (0.33) | CA2 | |
| SCHEMBL31139288 | 0.75 | KMT2A (0.33) | — | |
| SCHEMBL5196530 | 0.75 | MAPK1 (0.42) | — | |
| SCHEMBL5238331 | 0.74 | HTR2A (0.33) | HSD11B1 | |
| SCHEMBL25260943 | 0.72 | — | — | |
| SCHEMBL12659917 | 0.72 | CYP11B1 (0.36) | — | |
| SCHEMBL25617253 | 0.72 | CHRNB2 (0.31) | — | |
| SCHEMBL5198042 | 0.72 | POLB (0.38) | HSD11B1 | |
| SCHEMBL30542298 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776117-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013050-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | TACR2, TACR1, TAC3 | HSD11B1 1675/4885SLC22A12 2065/4885CA2 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.